References
- Lindquist S, Craig EA. The heat-shock proteins. Annu. Rev. Genet. 22, 631–677 (1988).
- Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu. Rev. Immunol. 20, 395–425 (2002).
- Srivastava PK, Callahan MK, Mauri MM. Treating human cancers with heat shock protein–peptide complexes: the road ahead. Expert Opin. Biol. Ther. 9(2), 179–186 (2009).
- Calderwood SK, Theriault J, Gray PJ, Gong J. Cell surface receptors for molecular chaperones. Methods 43(3), 199–206 (2007).
- Wang XY, Facciponte J, Chen X, Subjeck JR, Repasky EA. Scavenger receptor-A negatively regulates antitumor immunity. Cancer Res. 67(10), 4996–5002 (2007).
- Qian J, Yi H, Guo C et al. CD204 suppresses large heat shock protein-facilitated priming of tumor antigen gp100-specific T cells and chaperone vaccine activity against mouse melanoma. J. Immunol. 187(6), 2905–2914 (2011).
- Henderson B, Calderwood SK, Coates AR et al. Caught with their PAMPs down? The extracellular signalling actions of molecular chaperones are not due to microbial contaminants. Cell Stress Chaperones 15(2), 123–141 (2010).
- Murshid A, Gong J, Calderwood SK. Heat-shock proteins in cancer vaccines: agents of antigen cross-presentation. Expert Rev. Vaccines 7(7), 1019–1030 (2008).
- Graner M, Raymond A, Akporiaye E, Katsanis E. Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines. Cancer Immunol. Immunother. 49(9), 476–484 (2000).
- Enomoto Y, Bharti A, Khaleque AA et al. Enhanced immunogenicity of heat shock protein 70 peptide complexes from dendritic cell–tumor fusion cells. J. Immunol. 177(9), 5946–5955 (2006).
- Oki Y, Younes A. Heat shock protein-based cancer vaccines. Expert Rev. Vaccines 3(4), 403–411 (2004).
- Wang XY, Chen X, Manjili MH, Repasky E, Henderson R, Subjeck JR. Targeted immunotherapy using reconstituted chaperone complexes of heat shock protein 110 and melanoma-associated antigen gp100. Cancer Res. 63(10), 2553–2560 (2003).
- Manjili MH, Henderson R, Wang XY et al. Development of a recombinant HSP110-HER-2/neu vaccine using the chaperoning properties of HSP110. Cancer Res. 62(6), 1737–1742 (2002).
- Manjili MH, Wang XY, Chen X et al. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice. J. Immunol. 171(8), 4054–4061 (2003).
- Park JE, Facciponte J, Chen X et al. Chaperoning function of stress protein grp170, a member of the hsp70 superfamily, is responsible for its immunoadjuvant activity. Cancer Res. 66(2), 1161–1168 (2006).
- Wang XY, Sun X, Chen X et al. Superior antitumor response induced by large stress protein chaperoned protein antigen compared with peptide antigen. J. Immunol. 184(11), 6309–6319 (2010).
- Warger T, Hilf N, Rechtsteiner G et al. Interaction of TLR2 and TLR4 ligands with the N-terminal domain of Gp96 amplifies innate and adaptive immune responses. J. Biol. Chem. 281(32), 22545–22553 (2006).
- Zuo D, Yu X, Guo C et al. Molecular chaperoning by glucose-regulated protein 170 in the extracellular milieu promotes macrophage-mediated pathogen sensing and innate immunity. FASEB J. 26(4), 1493–1505 (2012).
- Yu X, Guo C, Yi H et al. A multifunctional chimeric chaperone serves as a novel immune modulator inducing therapeutic antitumor immunity. Cancer Res. 73(7), 2093–2103 (2013).
- Andreakos E, Williams RO, Wales J, Foxwell BM, Feldmann M. Activation of NF-κB by the intracellular expression of NF-κB-inducing kinase acts as a powerful vaccine adjuvant. Proc. Natl Acad. Sci. USA 103(39), 14459–14464 (2006).
Website
- ClinicalTrials.gov. www.clinicaltrials.gov